UCB SA (VIE:UCB)

Austria flag Austria · Delayed Price · Currency is EUR
157.25
+2.25 (1.45%)
Last updated: May 19, 2025
29.64%
Market Cap 29.43B
Revenue (ttm) 6.15B
Net Income (ttm) 1.07B
Shares Out n/a
EPS (ttm) 5.48
PE Ratio 27.63
Forward PE 20.94
Dividend 0.97 (0.62%)
Ex-Dividend Date Apr 25, 2025
Volume n/a
Average Volume 126
Open 157.25
Previous Close 155.00
Day's Range 157.25 - 157.25
52-Week Range 121.30 - 197.55
Beta n/a
RSI 52.90
Earnings Date Jul 31, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange Vienna Stock Exchange
Ticker Symbol UCB
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial Statements

News

There is no news available yet.